VBL Therapeutics Announces First Quarter 2018 Financial Results

May 17, 2018

Conference Call and Webcast at 8:30am Eastern Time Today

TEL AVIV, Israel, May 17, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced financial results for the first quarter ended March 31, 2018 and provided a corporate update.

“We continue to advance the OVAL trial, our Phase 3 potential registration trial in platinum-resistant ovarian cancer, in collaboration with the GOG Foundation,” said Yael Cohen M.D., VP Clinical Development of VBL Therapeutic. “We are in the process of amending the protocol to include an interim analysis for evidence of an early efficacy signal with a potential readout from this analysis in the fourth quarter of 2019.”

“We are also advancing our MOSPD2 program for oncology and inflammatory indications and, at the recent American Academy of Cancer Research (AACR) meeting, presented new proof-of-concept on the use of a bispecific antibody to kill MOSPD2-expressing cancer cells,” said Dror Harats M.D., Chief Executive Officer of VBL Therapeutics. “VBL is well capitalized, with approximately $50 million in cash, which will enable us to continue the development of VB-111 and our deep pipeline through 2020.’

First Quarter and Recent Corporate Highlights:

-- Continued to treat patients in the ongoing Phase 3 OVAL trial, studying VB-111 in platinum-resistant ovarian cancer. The OVAL study has been designed to enroll up to 350 adult patients at approximately 70 clinical sites in the U.S. and Israel. -- The Company is modifying the OVAL protocol to incorporate an efficacy interim readout, which is expected to occur in the fourth quarter of 2019. -- The Company is conducting an in-depth analysis of the GLOBE study, including analysis of patient subgroups, in order to better understand the outcome of the study, the major difference between the Phase II and the GLOBE trial and the potential activity of VB-111 in rGBM. -- Presented late breaking research on the Company’s MOSPD2 oncology program at the American Association for Cancer Research (AACR) 2018 annual meeting. -- The data provide proof-of-concept on the use of a bispecific antibody to kill MOSPD2-expressing cancer cells, with potential applicability to solid tumors and myeloid malignancies. -- The MOSPD2 program was also featured in a presentation at the 17th MIXiii-BIOMED 2018 Conference and Exhibition, May 15-17 in Tel Aviv, Israel. -- VBL is developing its VB-600 series of antibodies targeting MOSPD2 for oncology and inflammatory applications. -- Awarded 8.9 million New Israeli Shekels (approximately US$2.5 million) non-dilutive grant by the Israel Innovation Authority (IIA). -- The funds will support the development of VB-111 as well as the Company’s Vascular Targeting System (VTS™) platform for therapeutic gene therapy. -- Appointed two senior pharmaceutical executives, Susan Kelley, M.D., and David Hastings, to its Board of Directors.

First Quarter Ended March 31, 2018 Financial Results:

-- Revenues: In 2017 the Company entered into an exclusive license agreement with NanoCarrier Co., Ltd. and received an up-front and a milestone payment of $17.0 million in aggregate, of which $0.2 million was recognized as of March 2018. -- Cash Position: Cash, cash equivalents and short-term bank deposits at March 31, 2018, were $49.9 million. Working capital at March 31 was $44.3 million. The Company expects that the current cash, cash equivalents and short-term bank deposits will be sufficient to fund operating expenses and capital expenditure requirements through 2020. -- R&D Expenses: Research and development expenses for the quarter ended March 31, 2018, were approximately $5.8 million, compared to approximately $4.1 million in the comparable period in 2017. R&D expenses are shown net of IIA grants. -- G&A Expenses: General and administrative expenses for the quarter ended March 31, 2018 were $1.4 million, compared to $1.1 million for the comparable period in 2017. -- Comprehensive Loss: The Company reported a comprehensive loss for first quarter ended March 31, 2018 of $7.2 million, or ($0.24) per share, compared to a net loss of $5.0 million, or ($0.19) per share in first quarter ended March 31, 2017.

Conference Call:

Thursday, May 17th @ 8:30am Eastern Time

US Domestic: 877-222-6394 International: 1-703-925-2702 Conference ID: 9993639 Webcast: https://edge.media-server.com/m6/p/zja7xger

Replays, Available through May 31, 2018

US Domestic: 855-859-2056 International: 1-404-537-3406 Conference ID: 9993639

About VBL

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding VB-111, including its clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2017. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR CONTACT:Michael RiceLifeSci Advisors, LLC(646) 597-6979

VASCULAR BIOGENICS LTD. CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) March, 31 December, 31 2018 2017 ---------- - ---------- - U.S. dollars in thousands ------------------------ - Assets CURRENT ASSETS: Cash and cash equivalents $ 8,583 $ 6,694 Short-term bank deposits 41,306 48,035 Trade receivables — 2,000 Other current assets 2,307 1,729 TOTAL CURRENT ASSETS 52,196 58,458 NON-CURRENT ASSETS: Property and equipment, net 8,222 7,128 Long-term prepaid expenses 64 103 TOTAL NON-CURRENT ASSETS 8,286 7,231 TOTAL ASSETS $ 60,482 $ 65,689 Liabilities and equity CURRENT LIABILITIES- Accounts payable: Trade $ 3,612 $ 3,058 Other 3,426 3,465 Deferred revenue 883 1,046 TOTAL CURRENT LIABILITIES 7,921 7,569 NON-CURRENT LIABILITIES- Severance pay obligations, net 128 128 Deferred revenue 2,092 2,092 TOTAL NON-CURRENT LIABILITIES 2,220 2,220 TOTAL LIABILITIES 10,141 9,789 EQUITY: Ordinary shares 57 57 Accumulated other comprehensive income 16 16 Additional paid in capital 222,675 221,055 Warrants 2,960 2,960 Accumulated deficit (175,367 ) (168,188 ) TOTAL EQUITY 50,341 55,900 TOTAL LIABILITIES AND EQUITY $ 60,482 $ 65,689

VASCULAR BIOGENICS LTD. CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) Three Months Ended March 31, ---------------------------- 2018 2017 ------------ ------------ U.S. dollars in thousands ---------------------------- REVENUES 163 - COST OF REVENUES (67 ) - GROSS PROFIT 96 - RESEARCH AND DEVELOPMENT EXPENSES, net $ 5,760 $ 4,144 MARKETING EXPENSES 235 - GENERAL AND ADMINISTRATIVE EXPENSES 1,395 1,105 OPERATING LOSS 7,294 5,249 FINANCIAL INCOME (145 ) (219 ) FINANCIAL EXPENSES 30 4 FINANCIAL EXPENSES (INCOME), net (115 ) (215 ) COMPREHENSIVE LOSS 7,179 5,034 LOSS PER ORDINARY SHARE Basic and diluted $ 0.24 $ 0.19 - -------------------------- Number of shares ---------------------------- WEIGHTED AVERAGE ORDINARY SHARES OUTSTANDING- Basic and diluted 29,887,254 26,907,172

Update hourly